Biomarker Diagnostics Drive Personalized Medicine #1 Update
But Path to Market is Still Rife with Hurdles Convergence of Genomics and Medicine At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual Property, commercialization, reimbursement, drug development and...
Auxilium (AUXL) Holding Up After Barron’s “Not-So-Great Math”
Auxilium (AUXL) shares held up today ($24.85 up 0.65%) after a June 28 article questioned the valuation of the stock. Revenues for the last quarter were $45.5M primarily from its Testim testosterone gel, with a loss of $8.6M.Analysts have high expectations for a recently approved drug Xiaflex...
Oncology Pipeline Update
Here is an update on Oncology Pipelines courtesy of Linda Pullan (lpullan@msn.com), a consultant who follows the sector. www.PullanConsulting.com Pfizer (PFE), Roche (RHHBY) and Novartis (NVS) are predicted to launch the most drugs. Some Pharma Companies Need to In-License in Oncology Now by...
Supergen(SUPG) in a Rally Mode at $2.43;Reiterate Buy
Supergen (SUPG) has been moving up steadily over the past few days since its low in the $2.10+ range this week.SUPG is in the Rayno Life Science Portfolio. The April 15,2010 high was $3.72.The balance sheet is strong with over $100M in cash,Shareholder Equity of $106M and no debt. Market Cap is...
Post-ASCO Doldrums
Market Risk is Up-Speculation Is Off-Look for Value The news out of ASCO was not that new and exciting but it is even harder to find anything positive to write about three weeks later. Investors are "hiding out". The overall market has cooled down from the recent rally and macro news has not...